India parliament passes bill backing regional biotech institute


India's lower house of parliament passed a bill this week to back a regional biotech center aimed at promoting expertise and research in South Asia and wider in the Asian region, the Business Standard newspaper reports.

The Regional Centre for Biotechnology--to be located in the northern state of Haryana--would offer degrees up to the doctorate level, while also serving as a home to academics with access to research facilities in biotechnology, the newspaper said. Funding and other details were not available.

India has lagged in comparison to other Asian nations such as Japan, China and Australia in growing a local biotech industry--although established drug companies such as Dr. Reddy's Laboratories are making a push into biosimilar and licensed drugs, while smaller firms in the space are also on the research scene.


Simplify and Accelerate Drug R&D With the MarkLogic Data Hub Service for Pharma R&D

Researchers are often unable to access the information they need. And, even when data does get consolidated, researchers find it difficult to sift through it all and make sense of it in order to confidently draw the right conclusions and share the right results. Discover how to quickly and easily find, synthesize, and share information—accelerating and improving R&D.

In November of last year, the government said it wanted to add 1,500 startups in the next 2 to 3 years in biotechnology--up from around 500 at the end of 2015. Currently, India's biotech industry is around 2% of the global biotech sector and ranked 12th in the world and third in the Asia-Pacific region, according to a recent report.

The new center would seek to aid growth domestically in biotech as well as establish links abroad by offering course work training and research in biotechnology to students and researchers.

- here's the story from Business Standard


Suggested Articles

Acadia's knew it had a winner in psychosis when it called off a trial for its Nuplazid. Now analysts are seeing a blockbuster in the making.

Sandoz would still consider acquisitions, as long as they fit the Novartis unit's focus on generics and biosimilars, CEO Richard Saynor said.

Novartis is planning 80 major drug submissions in key markets over the next three years, and 25 of those could be blockbuster opportunities.